Exozymes Secures Additional $5.95M in Equity Offering After Underwriter Exercises Over-Allotment
EXOZ is trading near its 52-week low of $6.33 (0.0% above the low) on elevated volume (3.2× avg).
Summary
Exozymes has completed its underwritten equity offering, raising $5.95 million in gross proceeds after the underwriter exercised a portion of its over-allotment option. This follows the initial pricing of a $5.3 million unit offering on June 8th, which included common stock and warrants. The company has repeatedly disclosed substantial doubt about its ability to continue as a going concern in recent 10-K and 10-Q filings. The additional capital from the over-allotment provides crucial liquidity for the company, which has been burning cash and facing significant financial challenges. Proceeds will fund R&D, product development, and working capital.
At the time of this announcement, EXOZ was trading at $6.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.7M. The 52-week trading range was $6.33 to $18.40. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.